A Phase 1 Dose Escalation Study Of The Safety And Pharmacokinetics Of Lam-002A (Apilimod Dimesylate Capsules) Administered Orally In Subjects With Relapsed Or Refractory B-Cell Non-Hodgkin'S Lymphoma
Brief description of study
This is a Phase 1 dose exploration study of LAM-002A administered by mouth in patients with relapsed or refractory B-cell NHL. Safety, tolerability, pharmacokinetics (PK) and preliminary activity will be evaluated.
Clinical Study Identifier: s16-00762
ClinicalTrials.gov Identifier: NCTs16-00762
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
